China’s state-owned pharma company Sinopharm’s Covid-19 vaccine has received emergency use authorisation (EUA) from the World Health Organization (WHO). Sinopharm’s vaccine is the first Covid-19 vaccine developed by a non-western country to get approval from the WHO. The approval was based on a review of latest clinical data and manufacturing practices of the vaccine.
The European Medicines Agency (EMA) has initiated a rolling review of data on GlaxoSmithKline and Vir Biotechnology’s investigational dual-action SARS-CoV-2 monoclonal antibody, sotrovimab, for treatment of Covid-19 patients aged 12 and older. EMA will assess data on sotrovimab, which includes evidence gathered from clinical trials, as they become available.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Shanghai-based pharma group Fosun Pharma has signed a $200m joint venture agreement with Germany’s BioNTech for domestic production and commercialisation of the latter’s messenger ribonucleic acid (mRNA) Covid-19 vaccine. Fosun Pharma will invest $100m to produce one billion vaccine doses a year, while BioNTech will invest a maximum of $100m in production technology and patents.
